Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

784
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
784
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

488
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
488
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

621
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
621
Hazard Ratio01:12

Hazard Ratio

638
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
638
Actuarial Approach01:20

Actuarial Approach

325
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
325
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Not Just Jaundice: Furosemide-Induced Yellow-Tinted Vision in Decompensated Liver Cirrhosis.

ACG case reports journal·2026
Same author

ICED OUT: integrated cold-chain eliminating disease outreach. Piloting a motorcycle-enabled laboratory transport system combatting visceral leishmaniasis in rural Kenya.

Frontiers in public health·2026
Same author

Renal Autotransplantation After Yang-Monti Neoureter Procedure: Surgical Case Report and Brief Literature Review.

Case reports in urology·2025
Same author

DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) Is More: A Rare Case of Acalculous Cholecystitis.

ACG case reports journal·2025
Same author

Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer.

Cancer·2025
Same author

Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2025

Related Experiment Video

Updated: Feb 17, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.2K

Cost-Effectiveness Analysis in Cancer Care.

Alex Chang, Daniel E Abbott

    Cancer Treatment and Research
    |December 6, 2017
    PubMed
    Summary

    Understanding the incremental cost of medical interventions is crucial for healthcare resource allocation. Cost-effectiveness analyses are essential for evaluating return on investment and addressing healthcare inequalities.

    Area of Science:

    • Health Economics
    • Medical Technology Assessment
    • Healthcare Policy

    Background:

    • Modern medical therapies are increasingly complex and costly.
    • Evaluating the value of new interventions is challenging.
    • Randomized clinical trials often do not address resource utilization.

    Purpose of the Study:

    • To highlight the importance of marginal cost and gain analysis for medical interventions.
    • To emphasize the role of cost-effectiveness analyses in healthcare decision-making.
    • To address healthcare resource utilization and inequalities.

    Main Methods:

    • Review of economic principles in healthcare.
    • Discussion of cost-effectiveness analysis methodologies.
    • Examination of return on investment for biomedical research and pharmaceuticals.

    More Related Videos

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
    06:46

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

    Published on: September 27, 2024

    938
    Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
    06:16

    Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

    Published on: August 9, 2024

    971

    Related Experiment Videos

    Last Updated: Feb 17, 2026

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
    09:19

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

    Published on: February 6, 2015

    9.2K
    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
    06:46

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

    Published on: September 27, 2024

    938
    Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
    06:16

    Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

    Published on: August 9, 2024

    971

    Main Results:

    • Incremental cost analysis provides insights beyond traditional clinical trials.
    • Cost-effectiveness studies are vital for objective evaluation of treatments.
    • Understanding economic impact is key to sustainable healthcare.

    Conclusions:

    • Cost-effectiveness analyses are instrumental in guiding healthcare resource allocation.
    • Objective economic evaluation is necessary for continued biomedical research funding.
    • These analyses can help mitigate inequalities in healthcare delivery.